A Study to Evaluate the Long-term Safety, Tolerability, and Efficacy of Subcutaneous Sonelokimab in Participants With Moderate to Severe Hidradenitis Suppurativa
Study sponsor: MoonLake Immunotherapeutics AG
Primary completion is the date data collection ends for the main study measures, not when results are published.
Primary completion2028-06-13Estimated
Enrollment · participants835Estimated
Source updated2026-06-08Last update listed in the registry record
No recorded changes are available for this view and time period. Our history may be incomplete; this does not establish that the trial stayed unchanged.